All News about Anaptysbio Inc
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_6692.png?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/10/05/aapharma_2.png?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/04e9e812-bf31-4349-997d-639cc0f17ebf/small/anaptysbio-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/09/19/aapharma_15.png?width=1200&height=800&fit=crop)
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround
September 19, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/09/13/image19.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_26519.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/09/12/aapharma_15.png?width=1200&height=800&fit=crop)
AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
September 12, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/09/02/aapharma_4.png?width=1200&height=800&fit=crop)
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
September 02, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/short_image_42.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/04/28/aapharma_2.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_2467.png?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
September 01, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/09/01/aapharma_2.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_16044.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/earnings_image_2532.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_364.jpg)
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_16027.jpeg?width=1200&height=800&fit=crop)
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 31, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_9945.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_9441.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_9692.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/roce_image_1477.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/04/28/cells-gdd37bc5d2_1920.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/analyst_ratings_image_5261.jpeg)
![](https://cdn.benzinga.com/files/images/story/2012/cells-gdd37bc5d2_1920_18.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2012/aapharma_3839.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2012/cells-gdd37bc5d2_1920_16.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_4298.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/roce_image_608.jpeg)
![](/images/schema-image-default.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.